Inceptive
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Inceptive - overview
Established
2021
Location
Palo Alto, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2021 by Jakob Uszkoreit, Inceptive Nucleics, Inc. is a biotechnology company that develops software solutions to help medical professionals to design novel medicines and biotechnologies. In September 2023, Inceptive raised USD 100 million in Series A funding co-led by investors NVIDIA Corporation and Andreessen Horowitz, with participation from Obvious Ventures. As of 2023, the company operates from locations in Palo Alto, US, and Berlin, Germany.
The firm develops an AI (Artificial Intelligence)- powered biological software that helps researchers to design, create and test unique mRNA sequences that help in the development of novel medicines and biotechnologies.
Current Investors
Andreessen Horowitz, Obvious, Section 32
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT, Pharmaceutical Research & Development, Medical Software
Website
www.inceptive.life
Verticals
Artificial Intelligence, Artificial Intelligence
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.